Taizong Biotech Co., Ltd. 2026 Q1 EPS -0.45 TWD
Taizong Biotech Co., Ltd. announced its Q1 2026 financial results, reporting a net loss with an EPS of -0.45 TWD. The company generated 173 million TWD in revenue and a net profit of -26 million TWD, indicating a challenging quarter for the biotechnology and medical company.
📋 Article Processing Timeline
- 📰 Published: March 1, 2026 at 09:00
- 🔍 Collected: May 12, 2026 at 08:00 (1727h 0m after Published)
- 🤖 AI Analyzed: May 12, 2026 at 08:29 (29 min after Collected)
Taizong Biotech Co., Ltd. (stock code: 4169), a player in the biotechnology and medical industry, has released its financial report for the first quarter of 2026. The company recorded a basic earnings per share (EPS) of -0.45 TWD. Total operating revenue for the quarter was 173 million TWD, while the net profit after tax stood at -26 million TWD, reflecting a net loss for the period. This performance suggests that the company is undergoing significant investment in its development pipeline or facing market headwinds, prioritizing long-term growth and innovation.